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Abstract: During treatment of acute-phase schizophrenia, attention needs to be given to 
physical as well as psychological symptoms. It is often difficult, however, to obtain informa-
tion on physical symptoms from patients with psychomotor excitation, and only laboratory 
examinations can provide objective data. The results of laboratory parameters measured in 68 
patients with schizophrenia during psychomotor excitation and approximately 1 month later 
during the medicated recovery phase have been analyzed retrospectively. Abnormal laboratory 
values during psychomotor excitation were frequent. The most frequent ($35% of patients) 
were increased white blood cell count, low serum potassium levels, high levels of fasting 
blood sugar, lactate dehydrogenase and uric acid. There were fewer abnormal values during 
the medicated recovery phase. The most frequent ($25% of patients) were high serum levels 
of triglycerides, amylase, creatinine kinase, and low-density lipoprotein cholesterol. Abnormal 
triglyceride levels were found significantly more frequently in patients receiving olanzapine 
than those receiving risperidone. Abnormal values during the acute phase may be the result of 
excitation such as increased sympathetic tone and dehydration. Abnormal values during the 
recovery phase appeared to be related to the adverse metabolic effects of antipsychotic drugs. 
The frequency of these abnormal values was particularly high in patients receiving olanzapine 
alone or in combination with other medications.
Keywords: schizophrenia, laboratory test values, acute phase, recovery phase, risperidone, 
olanzapine
It has been estimated that up to 20% of psychiatric patients admitted to hospital are 
acutely agitated to an extent that requires physical restraint.1 In the treatment of acute-
phase schizophrenia, consideration has to be given to both physical and psychological 
symptoms. It is often difficult, however, to obtain information about medical history and 
physical symptoms from acutely agitated patients. It is therefore often necessary to 
rely on objective data such as the results of laboratory measures. The frequency of 
abnormal laboratory values in acutely agitated patients with schizophrenia was investi-
gated. For comparison the same measures were taken during the recovery phase under 
medication approximately 1 month later.
Method
Patients admitted to Kitunan Hospital in Suzenji, Japan from May 1999 and April 
2007 with acute psychomotor excitation were studied retrospectively. The inclusion 
criteria were: (i) patients diagnosed with schizophrenia according to the Diagnostic 
and Statistical Manual of Mental Disorders, 4th edition (DSM-IV); (ii) achieving a Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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score of at least 20 on the Excited component of the Positive 
and Negative Syndrome Scale (PANSS-EC) scale at hospital 
admission; and (iii) with laboratory values recorded at hos-
pital admission and 3–5 weeks later.
The PANSS-EC comprises five items from the PANSS:2 
poor impulse control, tension, hostility, uncooperativeness, 
and excitement, each rated on a 7-point Likert scale ranging 
from 1 (not present) to 7 (extremely severe). Possible scores 
range from 5 to 35; mean scores $20 indicate severe agitation.3 
Patients with alcoholism and/or drug abuse were excluded.
All laboratory tests performed on eligible patients at hos-
pital admission were examined. Values outside the reference 
range were defined as abnormal values, and the frequency of 
abnormal values was calculated for each parameter during 
the acute phase and during the recovery phase on medication, 
between 3 and 5 weeks later.
PANSS-EC scores between the acute and recovery phases 
were compared using paired t tests. For comparison between 
drugs for age, dose, and PANSS-EC score, unpaired t tests 
were used. For comparison of the frequency of abnormal 
values in the acute and recovery phases, as well as a com-
parison between drugs in the frequency of abnormal values, 
a chi-square (χ2) test was used. The significant level was set 
at P , 0. 05.
Results
Demographic characteristics
A total of 68 participants were included in the study (32 male, 
36 female). Mean age ± standard deviation was 47.0 ± 11.9 
years, and the mean PANSS-EC score ± standard deviation 
at hospital admission was 21.4 ± 1.5. Of the 37 participants 
with detailed records of previous hospital visits, 31 (83.8%) 
had interrupted their prescribed medication. Other patients 
were nonmedicated at admission.
As part of the retrospective analysis, treatment groups 
were defined according to the antipsychotic drug that had 
been used: risperidone group (14 participants), olanzapine 
group (16 participants), haloperidol group (12 participants), 
and a polypharmacy group defined as patients that had 
taken either risperidone and haloperidole, or olanapine and 
haloperidole. The medication prescribed was decided by 
the physician in charge at the time of their hospitalization. 
No information was available in the patient files as to the 
reason for the choice of a particular drug. Patients had taken 
no antipsychotic drugs other than risperidone, olanzapine, or 
haloperidol. Table 1 shows age, sex, and PANSS-EC score 
during the acute and recovery phase by drug. No significant 
differences in age or PANSS-EC score were found between 
the treatment groups during the acute phase. Conversion of 
doses of the antipsychotic drugs into chlorpromazine equiva-
lent doses showed that the polypharmacy group received 
significantly higher doses compared to the risperidone and 
olanzapine groups (P , 0.01).
As shown in Figure 1, all treatment groups had a 
significantly improved PANSS-EC score by weeks 3–5 
(P , 0.001), although there was significantly less reduction 
of PANSS-EC score in the polypharmacy group compared 
to the risperidone and olanzapine groups (P , 0.01).
Frequency of abnormal values
The reference values for 26 laboratory parameters and num-
ber of participants with values outside the reference range 
in the acute and recovery phases are summarized in Table 2. 
Laboratory parameters were classified into three groups 
depending on the frequency of abnormal values during the 
acute and recovery phases: (i) parameters with a high fre-
quency ($25%) of abnormal values during the acute phase 
and a low frequency (#25%) during the recovery phase white 
blood cells (WBC), platelets, Creative protein (CRP), fetal 
bovine serum (FBS), lactate dehydrogenase (LDH), blood 
urea nitrogen (BUN), uric acid (UA), K, Na, and Cl); (ii) 
parameters with a low frequency of abnormal values during 
the acute phase and a high frequency during the recovery 
phase (HbA1c, TG, LDL-C, Amy, and CK); and (iii) param-
eters with a low frequency of abnormal values during both 
the acute and recovery phases (RBC, Hb, T.Cho, HDL-C, TP, 
Table 1 Demographic characteristics
Age (years) Male/Female Dose (chlorpromazine-
equivalent dose) mg
PANSS-EC  
(acute phase)
PANSS-EC 
(recovery phase)
47.0 ± 11.9 32/36 804 ± 323 21.4 ± 1.5 11.4 ± 2.8
risperidone 46.6 ± 13.1 7/7 5.7 ± 2.1 (571 ± 205) 21.5 ± 1.4 9.7 ± 2.5
Olanzapine 43.1 ± 13.3 7/9 17.2 ± 3.5 (688 ± 141) 21.3 ± 1.5 10.5 ± 2.5
haloperidol 48.3 ± 9.3 6/6 16.5 ± 4.2 (825 ± 208) 21.9 ± 1.6 11.6 ± 2.4
Polypharmacy 49.1 ± 10.8 12/14 (992 ± 380)* 21.3 ± 1.3 12.8 ± 2.6*
Notes: *P , 0.01 versus ris or OLZ.
Abbreviation: PANss-ec, Positive and Negative syndrome scale, excited component.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Alb, AST, ALT, γGTP, T.Bil, and Cre). The full names of the 
parameters are shown in Table 2.
Parameters with a high frequency of abnormal values 
during the acute phase are shown in Figure 2 and those with 
a high frequency of abnormal values during the recovery 
phase in Figure 3. As shown in Figure 4, the frequency of 
abnormal values was significantly different between the 
acute and recovery phases for seven laboratory parameters 
(K, WBC, TG, LDH, UA, FBS, and BUN). Of these, 6 
parameters normalized during the recovery phase, while the 
frequency of abnormal triglyceride levels was greater during 
the recovery phase.
The frequency of abnormal values during the recovery 
phase in metabolism-related parameters is summarized in 
Figure 5. Abnormal triglyceride levels were significantly 
more frequent in the olanzapine group compared with the 
risperidone group (P = 0.031).
Discussion
The frequency of abnormal laboratory values during acute 
agitation and one month later during the recovery phase was 
investigated. Since it is often impossible to obtain informed 
consent from acutely agitated patients a retrospective noninter-
vention analysis was undertaken. Although this investigation 
suffers from the typical limitations of a retrospective study, 
it does provide data relevant to treatment in a typical clinical 
situation. Treatment with antipsychotic drugs resulted in a sig-
nificant improvement in PANSS-EC score in all cases. How-
ever, multidrug combination therapy tended to be   associated 
with higher doses and less improvement in PANSS-ES scores 
after 3–5 weeks compared with monotherapy with risperidone 
or olanzapine. This could indicate a lesser efficacy of the 
combinations. Another interpretation, however, is that these 
patients were more difficult to treat, hence the decision by 
the clinician to give combination therapy.
Of the 26 laboratory parameters examined, there were 
only 11 parameters for which abnormal values were infre-
quently reported during both the acute and recovery phases, 
indicating the importance of systematically performing 
laboratory tests during the acute and recovery phases of 
schizophrenia.
A high frequency of abnormal values was reported for 10 
laboratory parameters during the acute agitation phase. Of these 
five were reported at a frequency $35%; WBC, K, FBS, LDH, 
Figure 1 PANss-ec scores during the acute and recovery phases. Acute phase = at hospital admission with no medication; recovery phase = on medication for 3–5 weeks. 
Notes: Values are presented as means. *P , 0.05 compared to patients receiving polypharmacy.
Abbreviation: PANss-ec, Positive and Negative syndrome scale excited component.
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and UA. For all of these the frequency of abnormal values was 
significantly lower after 3–5 weeks of treatment. In addition, the 
frequency of abnormal values of BUN was also significantly 
lower during the recovery phases. Thus, there appears to be a 
total of six laboratory parameters for which abnormal values 
are likely to occur during the acute excitation phase.
In the present study abnormal values were defined as 
those outside the reference range and thus could be higher or 
lower values. All participants with abnormal WBC had values 
higher than the reference range, implying leukocytosis. All 
participants with abnormal K levels had values lower than 
the reference range, indicating hypokalemia. Of the 28 par-
ticipants with abnormal FBS levels, 26 had hyperglycemia 
and the remaining two had hypoglycemia. All participants 
with abnormal LDH, UA, and BUN levels had values higher 
than the reference range. Thus, during acute agitation there 
were signs of leukocytosis, hypokalemia, hyperglycemia, and 
elevations in LDH, UA, and BUN.
51 
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46 
44 
35  35 
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Figure 2 Laboratory parameters with a high frequency of abnormal values during the acute phase. Values are % patients presenting abnormal values.
Abbreviations: WBc, white blood cells; K, potassium; FBs, fasting blood sugar; LDh, lactate dehydrogenase; UA, uric acid.
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Figure 3 Laboratory parameters with a high frequency of abnormal values during the recovery phase. Values are % patients presenting abnormal values.
Abbreviations: Tg, triglyceride; Amy, amylase; cK, creatinine kinase; LDL-c, low-density-lipoprotein cholesterol.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Leukocytosis and hypokalemia seen during acute agitation 
were likely to be caused by the increased sympathetic tone 
which accompanies psychomotor excitation. The mecha-
nism causing these abnormal laboratory values is thought to 
be the restraint of circulation of leukocytes by sympathetic 
tone, and the inflow of serum K into muscle cells during 
catecholaminergic stimulation.4 Other findings that support 
this hypothesis include: (i) the low frequency of abnormal CRP 
levels despite an increase in WBC; (ii) the lower frequency of 
abnormal levels of Na and CI than of hypokalemia; and (iii) 
the lower frequency of abnormal Cre levels related to renal 
function. Finally when an improvement in PANSS-EC score 
was achieved, the frequency of these abnormal values was 
decreased, supporting a mechanism involving increased sym-
pathetic tone via increased   endogenous   catecholamine   activity. 
  Hyperglycemia may also be induced by   catecholamines.5 UA 
and BUN levels higher than the reference range may result from 
blood concentration due to excitation and dehydration.4
0
20
RIS OLZ HAL POLY
40
60
80
100
%
FBS
HbA1c
TG
LDL-C
P = 0.031
Figure 5 Frequency of abnormal values for parameters related to metabolism during the recovery phase by drug. Values are % patients presenting abnormal values.
Abbreviations: FBs, fasting blood sugar; hbA1c, hemoglobin A1c; Tg, triglyceride; LDL-c, low-density lipoprotein cholesterol. ris, risperidone; OLZ, olanzapine; hAL, 
haloperidol; POLY, polypharmacy.
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Figure 4 Laboratory parameters where the percentage of abnormal values were significantly changed between the acute and recovery phases. Values are % patients 
presenting abnormal values.
Abbreviations: K, potassium; WBc, white blood cells; Tg, triglyceride; LDh, lactate dehydrogenase; UA, uric acid; FBs, fasting blood sugar; BUN, blood urea nitrogen.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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During the acute agitation patients are under considerable 
psychological and physical stress and treatment with an antip-
sychotic drug is immediately required. At the same time, it is 
necessary to perform adequate physical monitoring, including 
laboratory parameters. Abnormal laboratory values should 
not, however, be regarded simply as   manifestations of specific 
organ dysfunction and the effects of psychological symptoms 
(agitation, excitation) should taken into account.
Although in general there were less laboratory parameters 
with abnormal values in the recovery period, four parameters 
had a high frequency ($25%) of abnormal values during 
the recovery phase: TG, Amy, CK, and LDL-C. For all four 
parameters the values were higher than the reference range. 
TG, however, was the only parameter for which the frequency 
of abnormal values was significantly increased during the 
recovery phase compared to the acute phase.
In general the recovery phase was characterized by an 
increased frequency of abnormal values for parameters 
related to metabolism. The improvement in psychological 
symptoms and adverse effects of antipsychotic drugs are both 
potential explanations for the increase in abnormal values 
for parameters related to metabolism. The calming of the 
agitation and psychomotor excitation results in a shift from 
catabolism during the excitation to anabolism during the 
recovery phase. In addition the well characterized adverse 
effects of antipsychotic drugs on the metabolic system are 
also likely to induce abnormal values.6
The frequency of abnormal values for FBS, HbA1c, TG, 
and LDL-C were all highest in the olanzapine group. The 
frequency of abnormal values for TG, in particular, was 
significantly higher in the olanzapine group compared with 
the risperidone group (P = 0.031). In an earlier study in 
which the laboratory data during the chronic phase during 
treatment with olanzapine and risperidone were compared, 
values for triglycerides and its intermediate metabolite, 
remnant-like cholesterol (RLP) were significantly higher 
with olanzapine compared with risperidone.7 Results of 
the Clinical Antipsychotic Trials of Intervention Effective-
ness (CATIE) trials have shown that the dropout rate due to 
metabolic abnormalities was significantly higher with olan-
zapine and that increased triglyceride levels were frequently 
reported with this drug.8 Increased triglyceride levels after 
meals are thought to constitute one of the important factors 
leading to cardiovascular events.9 Results of a study analyz-
ing triglyceride levels after meals in CATIE showed that 
olanzapine caused significant increases.10 Thus, laboratory 
tests should be performed on a regular basis, especially in 
patients taking olanzapine.
The polypharmacy group had the second highest fre-
quency of abnormal values after the olanzapine group. 
  Multidrug combination therapy is thought to be   associated 
with higher frequencies of metabolic syndrome and 
TG/HDL-C   values greater than 3.5 are indicative of 
insulin resistance.11 As explained above, olanzapine and 
polypharmacy appear to be associated with risk for meta-
bolic abnormalities. In the present study, the frequency of 
abnormal values for parameters related to metabolic effects 
during the recovery phase was increased in the olanzapine 
and polypharmacy groups, and the incidence of metabolic 
abnormalities appeared to vary depending on the type and 
number of antipsychotic drugs. The frequency of abnormal 
values during the recovery phase may depend on the type of 
antipsychotic drug.
Eleven participants had increased CK levels; 11.1% (1 of 
9) in the risperidone group, 50% (5 of 10) in the olanzapine 
group, 14.3% (1 of 7) in the haloperidol group, and 40% 
(4 of 10) in the polypharmacy group. This finding also shows 
that, as reported for metabolic abnormalities, increased CK 
levels tended to be more frequent in the olanzapine and 
polypharmacy groups. Results of a study determining CK 
levels in patients with chronic-phase schizophrenia indicated 
that CK levels increased when olanzapine was used relative 
to typical antipsychotics, suggesting a probable metabolic 
problem in muscle cells.12
Out of a total of nine participants in whom amylase 
(Amy) levels were determined, the three who had abnormal 
values were all treated with olanzapine. It is interesting 
that the frequency of abnormal values for CK and Amy 
by drug was similar to that of metabolic abnormalities. 
Although in this research it is proposed that increased CK 
and Amy levels may be related to metabolic abnormalities, 
this needs to be further investigated because of the small 
sample size used.
There were certain specific limitations to the present 
study: (i) it was a nonrandomized retrospective study; 
(ii) abnormal values were determined using standard refer-
ence values, with no adjustment for age or sex; and (iii) the 
severity of abnormal values (the extent to which they exceeded 
the standard range) was not to taken into account.
Conclusion
The frequencies of abnormal laboratory values during the 
acute and recovery phases of schizophrenia were inves-
tigated. During the acute agitation phase, the frequency 
of abnormal values for WBC, K, FBS, LDH, UA, and 
BUN was high. The reason for this appeared to be the Neuropsychiatric Disease and Treatment
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physical stress associated with agitation and excitation, 
such as increased sympathetic tone and dehydration. Dur-
ing the recovery phase, there was an increased frequency 
of abnormal values for parameters relating to metabolism. 
This may be ascribable to adverse effects of antipsychotic 
drugs. Olanzapine or polypharmacy appear to be associ-
ated with more abnormal values compared to risperidone 
and haloperidol.
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